Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

Phase 4

Completed

Conditions: Onychomycosis

Interventions: Drug: Terbinafine
Device: Resin Lacquer
Drug: Amorolfine

Registration Number: NCT01851590

Lead Sponsor: Helsinki University Central Hospital

Brief Summary: The current study is conducted to corroborate the previous observational clinical trial with more valid methods and a more clinically relevant experimental design. This study aims to compare efficacy, safety, and cost between topically administered 30% resin lacquer for the treatment of dermatophyte toenail onychomycosis and the current "best practices": topical 5% amorolfine and systemic terbinafine.

Detailed Description: The aim of this prospective, investigator-blinded, randomized and controlled clinical trial is to explore potential differences between 5 % amorolfine and 30 % resin lacquer in topical treatment of onychomycosis. In addition, topical treatment methods are compared with the most effective 'drug of choice' for onychomycosis according the current guidelines i.e. oral medication with terbinafine.

Altogether 90 patients (the aim is to collect the 30 patients per group) who have culture or potassium hydroxide (KOH) stain verified dermatophyte onychomycosis are randomly allocated into 3 treatment groups to receive either topical treatment or oral medication for toenail onychomycosis classified as follows:

1. White superficial onychomycosis (WSO)

2. Distal and lateral subungual onychomycosis (DLSO)

3. Proximal subungual onychomycosis (PSO)

4. \[Total dystrophic onychomycosis) (TDO)\] \[Excluded\]

5. \[Candidal onychomycosis\] \[Excluded\]

Participants are randomized into 3 groups to receive:

1. Topical treatment: 30 % resin lacquer (Abicin®) applied once daily for 9 months.

2. Topical treatment: 5 % amorolfine lacquer (Loceryl®) applied once weekly for 9 months.

3. Oral medication: 250 mg terbinafine taken orally once daily for 3 months.

All patients visit at outpatient department before the launch of the study, and 3 and 9 months thereafter. Clinical examination is done by 4 physicians. During the 42-week study period, laboratory tests are conducted on samples collected before treatment, at 20 weeks, and at 42 weeks. The tests include a fungal culture, KOH staining of the toenail sample, and blood tests. Cultures and KOH microscopy are performed in an independent, specialised mycology laboratory with standard techniques (Medix Laboratories Ltd., Helsinki, Finland). The blood tests measure plasma γ-glutamyl transferase levels (also at 2 weeks); plasma creatinine levels; the total number of white blood cells, including neutrophils, monocytes, basophils, lymphocytes, and eosinophils; the total number of red blood cells, including erythrocytes and haematocrit; erythrocyte indices, including the mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, and haemoglobin level; and the total number thrombocytes (initially and at 42 weeks). During the control visits, sequential digital photographs of the most disfigured and brittle toenails are acquired.

In the three phone calls, patients are asked about potential treatment-related side effects, compliance with treatment, patients' perception of treatment outcome, and their willingness to continue in the study. In each treatment arm, the treatment regimen is discontinued 5 weeks before the last toenail sampling to provide an appropriate washout period before the final culture and KOH analysis.

To ensure safety and to assess potential contraindications for the treatment regimens, all patients included in the study undergo a comprehensive medical interview and physical examination. To identify patients who may develop intolerable adverse events due to drug combinations, all concurrent medications are cross-checked to verify compatibility with resin, amorolfine, and terbinafine regimens at the beginning of the study. All patients are informed of the possibility of developing a hypersensitivity to resin, amorolfine, or terbinafine. If patients experienced symptoms that corresponded to any level of hypersensitivity, they are dropped from the study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 129

Inclusion Criteria

Positive dermatophyte culture in the beginning of the study obtained from the toenail sample.
Positive KOH stain in the beginning of the study obtained from the toenail sample.

Exclusion Criteria

Any other nail disease than dermatophyte culture or KOH stain verified onychomycosis
Onychomycosis caused by yeasts or nondermatophyte molds
Kidney failure determined by plasma creatinine level (P-Krea > 100 μmol/l)
Liver failure determined by plasma γ-glutamyltransferase level (P-GT > 120 U/I)
Sensitivity or allergy to Resin, Amorolfine or Terbinafine
Potential adverse cross-reaction of Terbinafine, Amorolfine or Resin with the patient's permanent medication
Presence of total dystrophic onychomycosis (TDO)
Any topical or oral antifungal treatment within the 6 months before the beginning of the study (washout period > 6 months).

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Terbinafine	Terbinafine	250 mg of Terbinafine taken orally once daily for 3 months (Generics).
Resin Lacquer	Resin Lacquer	Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
Amorolfine	Amorolfine	Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).

Primary Outcome Measures

Name	Time	Method
Mycological Cure	At 4- and 10 months time-points from the beginning of the study.	To analyze the rate of complete mycological cure i.e. fungal eradication in terms of negative mycological culture AND negative potassium hydroxide (KOH) stain at 4- and 10 months time-points from the beginning of the study.

Secondary Outcome Measures

Name	Time	Method
Clinical Responses to the Treatments	At 4- and 10 months time-points from the beginning of the study.	Clinical responses to treatment were based on the proximal linear growth of healthy nail; thus, the clinical responses were classified as partial (evident proximal linear growth of healthy nail) or complete. Partial responses were defined as significant reductions in onycholysis, subungual hyperkeratosis, and streaks. A complete response was a fully normal appearance of the toenail.
Cost-effectiveness 2	At 10-month time-point	Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014. The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm. The results show the treatment costs (€) during the treatment period per patient in each group.
Cost-effectiveness 1	At 10-month time-point	Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014. The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm. The results show the treatment costs (€) per day per patient in each group.
Compliance to the Treatment	At 4-month time-point	Evaluation of compliance was based on patient self-reports of whether the treatment protocol was followed 100% (complete), 80% (good), 60% (moderate), or 40% (poor) of the time.